Mechanisms and risk factors for proarrhythmia with type Ia compared with Ic antiarrhythmic drug therapy.
about
Data-driven Decisions: The Importance of Clinical Trials in Arrhythmia Management.Predicting drug-induced slowing of conduction and pro-arrhythmia: identifying the 'bad' sodium current blockers.Update on Atrial Fibrillation: Restoration of Sinus Rhythm or Ventricular Rate Control?Variations in potassium concentration modify the inhibitory effect of lorcainide on myocardial Na(+)-K(+)-ATPase activity.Are antiarrhythmic drugs safe?Role of abnormal repolarization in the mechanism of cardiac arrhythmia.Antiarrhythmic drug classifications and the clinician: a gambit in the land of chaos.In vitro electrophysiological detection of iatrogenic arrhythmogenicity.Cardiac electrophysiology and conduction pathway ablation.Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications.Differences in corrected QT intervals at minimal and maximal heart rate may identify patients at risk for torsades de pointes during treatment with antiarrhythmic drugs.Tachycardiomyopathy: mechanisms and clinical implications.Effects of midaglizole, a new hypoglycaemic drug on the electrophysiological properties of guinea-pig papillary muscleAssessment of drug-induced proarrhythmias due to pilsicainide in patients with atrial tachyarrhythmias.Electrophysiological evaluation of moricizine in patients with sustained ventricular tachyarrhythmias: low efficacy and high incidence of proarrhythmia.Atrial fibrillationImpaired epicardial activation-repolarization coupling contributes to the proarrhythmic effects of hypokalaemia and dofetilide in guinea pig ventricles
P2860
Q33179799-4923268F-D0F2-4BB7-9693-9792AB3A83CBQ33812750-14469B2E-3B00-40F8-9EAA-E582DFFED3A1Q33843408-3E8EDB4F-D805-459B-8FBE-15866B79CDFDQ35872643-F133517F-1E73-42AB-9C1C-47A731991C43Q37938703-EB220D48-29F6-4490-8E8B-4BE7DA1CED4FQ39434566-F9B2C479-3261-49CD-BC10-C2ECAE8BE55FQ40388359-78645E67-3EDA-4659-9F2D-D459AE28177AQ40604023-E4753A7D-939A-4D43-BE54-D849E2E58878Q40795195-205EF63F-4C33-47C5-948B-8C04B5DBC8AEQ40938946-289E3172-E579-4C33-A5D6-B03B54C0C1BBQ41034793-C082DEE8-921B-4A78-B315-8B178D01C6E1Q41144998-5C945270-F70C-4EEE-AF2C-E1B44239DC9FQ41790594-DD76F8AD-4639-4FBE-9710-A2F7BDA519C4Q41988829-D03A7835-ABDB-4F1D-B9D9-43D24115F379Q46248100-E7A7CAE5-1691-47BD-8107-E67508654C0EQ56607936-9B05257F-15F9-48FB-ABD0-8195A2422BCCQ57097260-32FDE567-3781-4F1D-8ABD-5FD744681D35
P2860
Mechanisms and risk factors for proarrhythmia with type Ia compared with Ic antiarrhythmic drug therapy.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Mechanisms and risk factors fo ...... c antiarrhythmic drug therapy.
@en
type
label
Mechanisms and risk factors fo ...... c antiarrhythmic drug therapy.
@en
prefLabel
Mechanisms and risk factors fo ...... c antiarrhythmic drug therapy.
@en
P2093
P356
P1433
P1476
Mechanisms and risk factors fo ...... c antiarrhythmic drug therapy.
@en
P2093
Morganroth J
P304
P356
10.1161/01.CIR.80.4.1063
P407
P577
1989-10-01T00:00:00Z